An interventional study of Erdosteine and Standard of Care (SOC) in COPD, sponsored by Pierachille Santus, MD, PhD. Not yet recruiting at 1 site in Italy. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Pierachille Santus, MD, PhD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy — 42 open to participants now, 48 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Italy.
Among the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, this one is the 186th largest by planned enrollment of the 212 interventional ones that give a count, is one of 7 that started in 2026, is one of 77 with no phase, reaches primary completion later than 24 of the 47 other live ones, and was the 270th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →42 of the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy are open now. Recruiting first, the newest first:
Azienda Socio Sanitaria Territoriale di Lodi · Sites in Italy
Ages 18+
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Pfizer · Sites in Italy, United States, Argentina and 15 more countries
Ages 35–80
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
280 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 22 · Phase 3 81 · Phase 4 33
First in 2000; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 245 across the 212 interventional studies, 238 across the 68 observational. Of the 199 that completed or were terminated, 80 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 280 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Pierachille Santus, MD, PhD as lead sponsor.
Pierachille Santus, MD, PhD has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
13 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT05766046Ugo PastorinoLung Cancer Prevention Screening Programme in Italy | 2026-12-31 |
| NCT05720780Istituti Clinici Scientifici Maugeri SpARehabilitation Training With Music-support & Exercise Tolerance in COPD and CRF Patients. | 2026-12-31 |
| NCT07329946Pierachille Santus, MD, PhDImmuno-inflammatory Response of Erdosteine in COPD | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic obstructive pulmonary disease (COPD) remains a major contributor to global morbidity and mortality, exposing healthcare systems to a significant economical and social load. Indeed, acute severe COPD exacerbations are the events that contribute most to the overall disease burden. Current management strategies are aimed at maximizing symptom-free periods, reduce hospitalizations, improve exercise tolerance, overall health status, and quality of life. Key pathophysiological mechanisms involved in COPD exacerbations (defined as acute worsening of respiratory symptoms) include oxidative stress, acute on chronic inflammation, and mucus hypersecretion. Agents with antioxidant, anti-inflammatory, and mucolytic properties can help reduce exacerbation frequency. Erdosteine is a new-generation mucoactive molecule developed to overcome the limitations associated with traditional mucolytics. In fact, in addition to its mucolytic effects, erdosteine exhibits antioxidant and anti-inflammatory activities and may reduce bacterial adhesion to airway surfaces - features that may be beneficial in the prevention and management of exacerbations. Preliminary clinical findings (EQUALIFE and RESTORE studies) suggest that erdosteine, in add-on to chronic inhaled therapy, can reduce exacerbation rates, shorten hospital stay, and improve health-related quality of life in patients with COPD. However, studies that have investigated the pathobiological mechanisms behind such clinical effects are lacking.
The present study was constructed in order to investigate the mechanism of action of erdosteine on inflammation, oxidative stress pathways and immune response in patients with COPD. The secondary objectives of the study are to evaluate the effect of erdosteine on lung function tests in patients with COPD; to explore the effect of erdosteine on respiratory and COPD-related symptoms in patients with COPD; to assess the effect of erdosteine on exercise tolerance in patients with COPD. In order to do so, the investigator designed a pragmatic, low intervention, two-arms, monocenter, open-label, prospective, randomized, controlled trial, set in clinical practice. A total of 30 patients will be randomized by means of a 1:1 random allocation.
The active group (15 patients) will be assigned to Treatment Arm A (Erdosteine [Esteclin®] 300 mg, 1 tablet twice daily for 30 days), while the control group (15 patients) will be assigned to Treatment Arm B (Standard of Care - current standard inhalation therapy in use).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized to receive Erdosteine \[Esteclin®\] 300 mg, 1 tablet twice daily for 30 days
Drug: Erdosteine · Drug: Standard of Care (SOC)
Patients will be randomized to receive current standard inhalation therapy in use
Drug: Standard of Care (SOC)
Erdosteine tablets 300 mg, 1 tablet orally every 12 hours (twice daily) for 30 days
Also known as: Esteclin
Long acting beta-2 agonists and Long acting muscarinic antagonists in association (LABA/LAMA) with or without inhaled corticosteroids (LABA/LAMA/ICS) depending on the chronic inhaled home treatment. Dosage and posology will change depending on the molecules and the devices (once daily in case of umeclidinium bromide/vilanterol 55/22 mcg or fluticasone/umeclidinium bromide/vilanterol 92/55/22 or twice daily in case of budesonide/formoterol/glycopyrronium 160/7.2/4.8 mcg and beclometasone/formoterol/glycopyrronium 87/5/9 mcg)
Changes in transcriptomics of pro-inflammatory and anti-inflammatory cytokines in COPD patients exposed to erdosteine.
Peripheral blood will be analyzed for immunological profiling in patients treated with standard of care only and patients also exposed to Erdosteine at baseline and after 4 weeks of treatment. Cytokine/chemokine profiles will be quantified in cell culture supernatants using the Bio-Plex Pro Human Cytokine 27-plex Assay. RNA extraction from whole blood will be performed to identify expression levels of molecules involved in immune response: CARD6, CASP1, CASP4, CCL2, HLA-A, IFITM1, IFNA1, IFNAR1, IL1β, IL6, IL8, IL10, IL17, IL18, IL22, ISG20, TGF-β, NLRP3, NLRP4, VCAM1. Betaactin (ACTB) and glyceraldeyde-3-phosphate dehydrogenase (GAPDH) will be used as housekeeping genes. The results for the gene expression analyses will be presented as the average of the relative expression units (%) to an internal reference sample and normalized to the housekeeping genes GAPDH and ACTB.
Time frame: 4 weeks
Changes in transcriptomics of oxidative stress signaling pathways in COPD patients exposed to erdosteine.
Peripheral blood will be analyzed for oxidative stress profiling in patients treated with standard of care only and patients also exposed to Erdosteine at baseline and after 4 weeks of treatment. Oxidative stress will be quantified in cell culture supernatants using the Bio-Plex Pro Human Cytokine 27-plex Assay. RNA extraction from whole blood will be performed to identify expression levels of molecules involved in oxidative stress: APOE, CAT, DUSP1, GPX2, GPX3, MPO, NOS2, NOX4, NUDT1, SOD2. Betaactin (ACTB) and glyceraldeyde-3-phosphate dehydrogenase (GAPDH) will be used as housekeeping genes. The results for the gene expression analyses will be presented as the average of the relative expression units (%) to an internal reference sample and normalized to the housekeeping genes GAPDH and ACTB.
Time frame: 4 weeks
To assess the effect of erdosteine on mMRC dyspnea scale in patients with COPD
Patiens will undergo the Modified British Medical Research Council Questionnaire (mMRC) at baseline and after 4 weeks of treatment with erdosteine or placebo. Modified British Medical Research Council Questionnaire (mMRC) assesses the patient's degree of chronic dyspnea with a score ranging from 0 (no dyspnea) to 4 (too much dyspnea to leave the house). The results will be expressed as absolute and relative difference in dyspnea score.
Time frame: 4 weeks
To assess the effect of erdosteine on distance covered during the six minute walk test in patients with COPD
Patiens will undergo the Six Minutes Walk Test (6MWT) at study enrolment and after 4 weeks of treatment with erdosteine or placebo. The 6MWT will be conducted according to the 2002 American Thoracic Society (ATS) statement. For patients requiring exertional oxygen therapy, the test will be performed with supplemental oxygen. Patients will be asked to walk for 6 minutes on a flat surface, wearing a pulse oximeter. Before starting, the following parameters will be recorded: perceived dyspnoea level using the Borg scale (0-10 score), peripheral oxygen saturation (SpO2), heart rate (beats/min), and respiratory rate (breaths/min). The same parameters will be measured again at the end of the test. The distance walked, and any exercise-induced desaturation (SpO2 drop ≥4 points) will also be noted. The distance covered at the 6MWT will be measured in meters, and results will be expressed as absolute and relative difference from baseline.
Time frame: 4 weeks
To assess the effect of erdosteine on CAT (COPD assessment test) in patients with COPD
Patiens will undergo the CAT (COPD assessment test) at baseline and after 4 weeks of treatment with erdosteine or placebo. COPD assessment test (CAT) aims to assess the impact of COPD on health status through a patient-completed questionnaire consisting of 8 items, each scored from 0 to 5. The total score ranges from 0 to 40, with higher scores indicating a greater impact of the disease on the patient's quality of life. The results will be expressed as absolute and relative difference in CAT total score.
Time frame: 4 weeks
To evaluate the effect of erdosteine on dynamic lung volumes in patients with COPD
Dynamic lung volumes, will be measured using a constant-volume body plethysmograph at study enrolment and after 4 weeks of treatment with erdosteine or placebo. The following volumes will be measured: forced expiratory volume in first second (FEV₁), forced vital capacity (FVC), slow VC, forced mid-expiratory flow at 25 and 75% of FVC (FEF25-75), expiratory reserve volume (ERV). The results will be expressed as absolute (liters) and % predicted value, and measured as absolute and relative difference from baseline.
Time frame: 4 weeks
To assess the effect of erdosteine on static volumes in patients with COPD
Static lung volumes will be measured using a constant-volume body plethysmograph according to current recommendations (Wanger et al. Eur Respir J 2005) at baseline and after 4 weeks of treatment with erdosteine or placebo. Patients will be instructed to breathe in seated position, wearing a nose clip, while connected to a pneumotachograph, with closed cabin. The following volumes will be measured: residual volume (RV), total lung capacity (TLC), RV/TLC and intrathoracic gas volume (ITGV). ITGV will be measured close to the end-expiratory lung volume during quiet breathing to obtain functional residual capacity (FRC). The results will be expressed as absolute (liters) and % predicted value, and measured as absolute and relative difference from baseline.
Time frame: 4 weeks
To evaluate the effect of erdosteine on lung diffusion capacity in patients with COPD
Lung diffusion capacity for carbon monoxide (DLCO) will be measured using a constant-volume body plethysmograph at study enrolment and after 4 weeks of treatment with erdosteine or placebo. DLCO, transfer factor (KCO), and alveolar volume (VA) will be measured using the single-breath technique. VA will be assessed by means of the inert gas dilution technique. The DLCO value will be corrected based on the most recent available hemoglobin value. The results will be expressed as absolute (mmol x min-1 kPa-1 for DLCO, mmol x min-1 kPa-1 1-1 for KCO, and liters for VA) and % predicted value, and measured as absolute and relative difference from baseline.
Time frame: 4 weeks
To evaluate the effect of erdosteine on specific airway resistances in patients with COPD
Specific airway resistances (sRAW) will be measured using a constant-volume body plethysmograph according to current recommendations (Wanger et al. Eur Respir J 2005) at baseline and after 4 weeks of treatment with erdosteine or placebo. Patients will be instructed to breathe tidally in seated position, wearing a nose clip, while connected to a pneumotachograph, with closed cabin. The results will be expressed as absolute (kPa x s) and % predicted value, and measured as absolute and relative difference from baseline.
Time frame: 4 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Feb 2027, 5 months later.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Erdosteine
Pulmonary Disease, Chronic Obstructive →